The global immunoncology drugs market is expected to grow at a CAGR of 12.2% during the forecast period, from 2021 to 2030. The growth of this market is driven by the increasing incidence of cancer and rising demand for immunotherapy drugs.
Immune checkpoint inhibitors are one of the major types in this market and are expected to grow at a CAGR of 13.5% during the forecast period, from 2021 to 2030. Monoclonal antibodies are another type in this market and are expected to grow at a CAGR of 11% during the forecast period, from 2021 to 2030. Cytokin-based immunotherapy is another type in this market and is expected to grow at a CAGR of 10% during the forecast period, from 2021 to 2030. Cancer vaccines are also one type in this market and they are expected to grow at a CAGR of 9% during the forecast period, from 2021-2030. CAT cell therapy is also one type in this market which will be growing with an estimated rate 8%, over next five years (from 2020-2025).
Some Of The Growth Factors Of This Market:
- The increasing incidence of cancer and rising awareness about the benefits of immunotherapy are some factors that are driving the growth of this market.
- Increasing research and development activities for new drug candidates in this segment is also expected to fuel the growth of this market during the forecast period.
- However, high cost associated with these drugs may hamper their adoption among patients globally which may restrain their growth during the forecast period .
Industry Growth Insights published a new data on “Immuno-oncology Drugs Market”. The research report is titled “Immuno-oncology Drugs Market research by Types (Immune Checkpoint Inhibitors, Monoclonal Antibodies, Cytokine-Based Immunotherapy, Cancer Vaccines, CAR-T Cell Therapy), By Applications (Hospitals, Pharmacies, Online Pharmacies), By Players/Companies Amgen, Inc, AstraZeneca, Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., Hoffmann-La Roche AG, Johnson & Johnson, Novartis International AG, AbbVie, Inc., Pfizer Inc., Sanofi S.A., EMD Serono, Inc., Gilead Sciences Inc., Prometheus Therapeutics & Diagnostics, Aduro BioTech, Galena Biopharma, Bavarian Nordic, Celldex Therapeutics, ImmunoCellular Therapeutics, Incyte”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Immuno-oncology Drugs Market Research Report
By Type
Immune Checkpoint Inhibitors, Monoclonal Antibodies, Cytokine-Based Immunotherapy, Cancer Vaccines, CAR-T Cell Therapy
By Application
Hospitals, Pharmacies, Online Pharmacies
By Companies
Amgen, Inc, AstraZeneca, Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., Hoffmann-La Roche AG, Johnson & Johnson, Novartis International AG, AbbVie, Inc., Pfizer Inc., Sanofi S.A., EMD Serono, Inc., Gilead Sciences Inc., Prometheus Therapeutics & Diagnostics, Aduro BioTech, Galena Biopharma, Bavarian Nordic, Celldex Therapeutics, ImmunoCellular Therapeutics, Incyte
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
242
Number of Tables & Figures
170
Customization Available
Yes, the report can be customized as per your need.
Global Immuno-oncology Drugs Market Report Segments:
The global Immuno-oncology Drugs market is segmented on the basis of:
Types
Immune Checkpoint Inhibitors, Monoclonal Antibodies, Cytokine-Based Immunotherapy, Cancer Vaccines, CAR-T Cell Therapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen, Inc
- AstraZeneca, Plc
- Bristol-Myers Squibb
- Celgene Corporation
- Eli Lilly and Company
- Merck & Co.
- Hoffmann-La Roche AG
- Johnson & Johnson
- Novartis International AG
- AbbVie, Inc.
- Pfizer Inc.
- Sanofi S.A.
- EMD Serono, Inc.
- Gilead Sciences Inc.
- Prometheus Therapeutics & Diagnostics
- Aduro BioTech
- Galena Biopharma
- Bavarian Nordic
- Celldex Therapeutics
- ImmunoCellular Therapeutics
- Incyte
Highlights of The Immuno-oncology Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Immune Checkpoint Inhibitors
- Monoclonal Antibodies
- Cytokine-Based Immunotherapy
- Cancer Vaccines
- CAR-T Cell Therapy
- By Application:
- Hospitals
- Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Immuno-oncology Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Immuno-oncology drugs are medications that help the body's immune system fight cancer. These drugs can be used in combination with other treatments to improve the chances of success.
Some of the key players operating in the immuno-oncology drugs market are Amgen, Inc, AstraZeneca, Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., Hoffmann-La Roche AG, Johnson & Johnson, Novartis International AG, AbbVie, Inc., Pfizer Inc., Sanofi S.A., EMD Serono, Inc., Gilead Sciences Inc., Prometheus Therapeutics & Diagnostics, Aduro BioTech, Galena Biopharma, Bavarian Nordic, Celldex Therapeutics, ImmunoCellular Therapeutics, Incyte.
The immuno-oncology drugs market is expected to grow at a compound annual growth rate of 12.2%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Immuno-oncology Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Immuno-oncology Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Immuno-oncology Drugs Market - Supply Chain
4.5. Global Immuno-oncology Drugs Market Forecast
4.5.1. Immuno-oncology Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Immuno-oncology Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Immuno-oncology Drugs Market Absolute $ Opportunity
5. Global Immuno-oncology Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Immuno-oncology Drugs Market Size and Volume Forecast by Type
5.3.1. Immune Checkpoint Inhibitors
5.3.2. Monoclonal Antibodies
5.3.3. Cytokine-Based Immunotherapy
5.3.4. Cancer Vaccines
5.3.5. CAR-T Cell Therapy
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Immuno-oncology Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Immuno-oncology Drugs Market Size and Volume Forecast by Application
6.3.1. Hospitals
6.3.2. Pharmacies
6.3.3. Online Pharmacies
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Immuno-oncology Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Immuno-oncology Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Immuno-oncology Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Immuno-oncology Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Immuno-oncology Drugs Demand Share Forecast, 2019-2026
9. North America Immuno-oncology Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Immuno-oncology Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Immuno-oncology Drugs Market Size and Volume Forecast by Application
9.4.1. Hospitals
9.4.2. Pharmacies
9.4.3. Online Pharmacies
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Immuno-oncology Drugs Market Size and Volume Forecast by Type
9.7.1. Immune Checkpoint Inhibitors
9.7.2. Monoclonal Antibodies
9.7.3. Cytokine-Based Immunotherapy
9.7.4. Cancer Vaccines
9.7.5. CAR-T Cell Therapy
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Immuno-oncology Drugs Demand Share Forecast, 2019-2026
10. Latin America Immuno-oncology Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Immuno-oncology Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Immuno-oncology Drugs Market Size and Volume Forecast by Application
10.4.1. Hospitals
10.4.2. Pharmacies
10.4.3. Online Pharmacies
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Immuno-oncology Drugs Market Size and Volume Forecast by Type
10.7.1. Immune Checkpoint Inhibitors
10.7.2. Monoclonal Antibodies
10.7.3. Cytokine-Based Immunotherapy
10.7.4. Cancer Vaccines
10.7.5. CAR-T Cell Therapy
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Immuno-oncology Drugs Demand Share Forecast, 2019-2026
11. Europe Immuno-oncology Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Immuno-oncology Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Immuno-oncology Drugs Market Size and Volume Forecast by Application
11.4.1. Hospitals
11.4.2. Pharmacies
11.4.3. Online Pharmacies
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Immuno-oncology Drugs Market Size and Volume Forecast by Type
11.7.1. Immune Checkpoint Inhibitors
11.7.2. Monoclonal Antibodies
11.7.3. Cytokine-Based Immunotherapy
11.7.4. Cancer Vaccines
11.7.5. CAR-T Cell Therapy
11.8. Basis Point Share (BPS) Analyis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Immuno-oncology Drugs Demand Share, 2019-2026
12. Asia Pacific Immuno-oncology Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Immuno-oncology Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Immuno-oncology Drugs Market Size and Volume Forecast by Application
12.4.1. Hospitals
12.4.2. Pharmacies
12.4.3. Online Pharmacies
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Immuno-oncology Drugs Market Size and Volume Forecast by Type
12.7.1. Immune Checkpoint Inhibitors
12.7.2. Monoclonal Antibodies
12.7.3. Cytokine-Based Immunotherapy
12.7.4. Cancer Vaccines
12.7.5. CAR-T Cell Therapy
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Immuno-oncology Drugs Demand Share, 2019-2026
13. Middle East & Africa Immuno-oncology Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Immuno-oncology Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Immuno-oncology Drugs Market Size and Volume Forecast by Application
13.4.1. Hospitals
13.4.2. Pharmacies
13.4.3. Online Pharmacies
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Immuno-oncology Drugs Market Size and Volume Forecast by Type
13.7.1. Immune Checkpoint Inhibitors
13.7.2. Monoclonal Antibodies
13.7.3. Cytokine-Based Immunotherapy
13.7.4. Cancer Vaccines
13.7.5. CAR-T Cell Therapy
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Immuno-oncology Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Immuno-oncology Drugs Market: Market Share Analysis
14.2. Immuno-oncology Drugs Distributors and Customers
14.3. Immuno-oncology Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Amgen, Inc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. AstraZeneca, Plc
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Bristol-Myers Squibb
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Celgene Corporation
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Eli Lilly and Company
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Merck & Co.
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Hoffmann-La Roche AG
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Johnson & Johnson
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Novartis International AG
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. AbbVie, Inc.
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Pfizer Inc.
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Sanofi S.A.
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. EMD Serono, Inc.
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Gilead Sciences Inc.
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Prometheus Therapeutics & Diagnostics
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Aduro BioTech
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. Galena Biopharma
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. Bavarian Nordic
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. Celldex Therapeutics
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. ImmunoCellular Therapeutics
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
